Pancreatic Cancer Research

ResearcherUniversity of BolognaActive in the last 2 years

Serena Langella

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2300-0460; OpenAlex author ID A5036669798. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  2. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  3. Impact of Textbook Oncologic Outcome on long term survival after resection for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.09.004↗
  4. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  5. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  6. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  7. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer pat… Co-author DOI 10.1007/s10238-023-01236-5↗
  8. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  9. A safe technique for radical antegrade modular pancreatosplenectomy with venous resection for pancreatic cancer. First author DOI 10.1016/j.jamcollsurg.2013.08.007↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Ferrero · 4 shared papers, 2023–2025 · strength 0.80
  2. Alessandro Cucchetti · 2 shared papers, 2024 · strength 0.36
  3. Giuseppe Malleo · 2 shared papers, 2024 · strength 0.36
  4. Giulio Belfiori · 2 shared papers, 2024 · strength 0.36
  5. Fabio Casciani · 2 shared papers, 2024 · strength 0.36
  6. Riccardo Casadei · 2 shared papers, 2024 · strength 0.36
  7. Claudio Ricci · 2 shared papers, 2024 · strength 0.36
  8. Giorgio Ercolani · 2 shared papers, 2024 · strength 0.36
  9. Gabriella Lionetto Lionetto · 2 shared papers, 2024 · strength 0.36
  10. Massimo Falconi · 2 shared papers, 2024 · strength 0.36
  11. Stefano Crippa · 2 shared papers, 2024 · strength 0.36
  12. Roberto Salvia · 2 shared papers, 2024 · strength 0.36
  13. Laura Antolino · 1 shared paper, 2025 · strength 0.30
  14. Carlo Ingaldi · 1 shared paper, 2024 · strength 0.18
  15. Vincenzo Mazzaferro · 1 shared paper, 2024 · strength 0.18
  16. Vincenzo D’Ambra · 1 shared paper, 2024 · strength 0.18
  17. Claudio De Angelis · 1 shared paper, 2023 · strength 0.14
  18. Claudia Curcio · 1 shared paper, 2023 · strength 0.14
  19. Elisabetta Fenocchio · 1 shared paper, 2023 · strength 0.14
  20. Silvia Brugiapaglia · 1 shared paper, 2023 · strength 0.14
  21. Rosella Spadi · 1 shared paper, 2023 · strength 0.14
  22. Francesco Novelli · 1 shared paper, 2023 · strength 0.14
  23. Daniel Jaeck · 1 shared paper, 2013 · strength 0.04
  24. Edoardo Rosso · 1 shared paper, 2013 · strength 0.04
  25. Pietro Addeo Md · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.